Abivax Invites You to an Engaging KOL Webcast
Abivax, a forward-thinking clinical-stage biotechnology company, is excited to announce a Key Opinion Leader (KOL) webcast focusing on ulcerative colitis treatments. This event promises valuable insights as it features the distinguished gastroenterologist, Dr. David T. Rubin.
Meet the Expert: Dr. David T. Rubin
Dr. Rubin, who leads the Inflammatory Bowel Disease Center at The University of Chicago, will share his expertise and address the nuances of ulcerative colitis in the upcoming webcast. With a wealth of knowledge, Dr. Rubin has become a trusted name in the treatment landscape of chronic inflammatory diseases.
Exploring Current Challenges in UC Treatments
During the webcast, Dr. Rubin will delve into the current challenges that patients with moderately to severely active ulcerative colitis face. His analysis will include the critical unmet medical needs and how emerging treatments, particularly Abivax’s obefazimod, aim to bridge these gaps.
Understanding the ABTECT Phase 3 Trial
A significant highlight of this event will be the discussion surrounding Abivax’s pivotal ABTECT Phase 3 trial. This clinical trial evaluates the efficacy of obefazimod, a promising therapeutic candidate, designed to stabilize immune responses in ulcerative colitis patients.
Webcast Details You Shouldn’t Miss
Mark your calendars for the KOL webcast on March 17, 2025, at 9:00 a.m. EDT. Participants will not only gain insights from Dr. Rubin's presentation but will also have the chance to engage directly in a Q&A session with him and the Abivax management team.
Registration Information
Interested attendees can register for the event online. Ensure you secure your spot to gain insights that could potentially shape the future of ulcerative colitis therapies.
About Abivax
Abivax is a clinical-stage biotechnology company with a mission to deliver pioneering therapies that leverage the body’s innate regulatory systems. The company is committed to addressing the pressing needs of patients suffering from chronic inflammatory diseases. Its lead drug candidate, obefazimod (ABX464), is currently undergoing evaluation in Phase 3 clinical trials for ulcerative colitis.
Staying Connected with Abivax
For ongoing updates and information regarding their progress, you can follow Abivax on social media platforms, including LinkedIn and X, formerly known as Twitter, under the handle @ABIVAX.
Frequently Asked Questions
What is the purpose of the KOL webcast hosted by Abivax?
The purpose of the KOL webcast is to provide insights into the treatment landscape for ulcerative colitis, featuring expert opinions and discussions about Abivax’s ABTECT Phase 3 trial.
Who will be speaking at the webcast?
The webcast will feature Dr. David T. Rubin, a leading gastroenterologist known for his expertise in inflammatory bowel diseases.
When is the KOL webcast scheduled?
The KOL webcast is set for March 17, 2025, at 9:00 a.m. EDT.
How can one register for the webcast?
Individuals can register for the webcast online; the registration link will be provided by Abivax prior to the event.
What is obefazimod, and how is it relevant to the webcast?
Obefazimod (ABX464) is Abivax's lead drug candidate in Phase 3 trials, aimed at treating moderately to severely active ulcerative colitis. It will be discussed in the context of the trial results and potential impacts on treatment.
